- The stock price of BioRestorative Therapies Inc (NASDAQ: BRTX) increased by over 45% pre-market today. This is why it happened.
The stock price of BioRestorative Therapies Inc (NASDAQ: BRTX) – a life sciences company focused on adult stem cell-based therapies – increased by over 45% pre-market today. Investors are responding positively to BioRestorative Therapies announcing it has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO) specializing in clinical trial management to conduct BioRestorative’s Phase 2 clinical trial.
PRC Clinical is known as an all-inclusive CRO and has specialized expertise across regenerative medicine, CNS, ophthalmology, pulmonary and COVID-19, rare and orphan disease, and more complex indications. And their innovative approach to executing studies for biotech and pharmaceutical companies combines high-touch human elements and cutting-edge technology with extensive experience and deep therapeutic knowledge. Pursuant to the agreement, PRC Clinical is going to manage BioRestorative’s Phase 2 clinical study of BRTX-100, the company’s lead clinical product to treat chronic lumbar disc disease.
“This is a significant milestone in our mission to develop cell-based therapeutics and to become a clinical-stage company. We believe that PRC’s renowned expertise in conducting clinicals trials and their use of innovative technology makes them an excellent CRO to partner with. This is the most meaningful step the Company has taken to initiate our clinical trial. We should now expect a host of developments pertaining to the advancement of our clinical trial, ultimately leading to the read-out of our primary endpoints.”
— Lance Alstodt, Chief Executive Officer of BioRestorative Therapies
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.